935106861
info@markelab.com
Precio
412.5€ (100 µg)
Sintilimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, Sintilimab is a fully human anti-PD-1 antibody for tumor immunotherapy. It adopts IgG4 molecular framework and modified its hinge region sequence (S228P). Sintilimab, as a programmed death receptor 1 (PD-1) blocker, can bind to PD-1 molecules on the surface of T cells and relieve the inhibitory effect of PD-1 pathway on T cells.
Biosimilars
Human
Monoclonal
Human
PDCD1/PD1/CD279
Human
IgG4 Kappa
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 2072873-06-2
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más